clinical trial · NCT06998056
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Atopic Dermatitis (Eczema)ARQ-151 cream 0.05%
brief summary
This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
started
Jun 9, 2025
primary completion
Dec 4, 2025
completion
Dec 4, 2025
last updated
Dec 10, 2025
detailed description
This study is an open label safety study in which ARQ-151 cream 0.05% is applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
official title
A Phase 2, Open Label, 4-Week, Safety Study of Roflumilast Cream 0.05% Administered Once Daily in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol